They observed that IFN-DCs preferentially migrate towards and phagocytose tumor cells that have been treated with interferon-α and romidepsin, thereby demonstrating the utility of the model for tracking immune-tumor cell interactions in real time and examining novel combination therapies. The gene discussed is IFNA1; the disease is neoplasm.